Company intelligence / Profile preview

Ho'ola Therapeutics

Delaware, United States

Ownership: Private
Development stage: Other

Overview

Ho'ola Therapeutics owns two advanced oncology programs acquired from Oncternal Therapeutics: zilovertamab, a monoclonal antibody that reached Phase 3, and ONCT-808, a CAR-T therapy targeting ROR1. While zilovertamab's Phase 3 trial under Oncternal was ended prematurely due to commercial challenges, ONCT-808 had reached clinical testing but was paused following a safety event. Both programs are now positioned for further development under Ho'ola Therapeutics.[1][2][3][4][5][8]

Therapeutic areas: OncologyHematology
Modalities: Monoclonal antibodyCAR-T cell therapyBiologicCell therapy
Industry: Biotech

Beyond the preview

Go deeper on Ho'ola Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ho'ola Therapeutics.

Explore the full profile